Benzothiazepine CGP37157 and its 2′-isopropyl analogue modulate Ca2+ entry through CALHM1

Neuropharmacology

Volumn 95, Issue , 2015, Pages 503-510

  Moreno Ortega, Ana J ^a,b   Martínez Sanz, Francisco J ^a   Lajarín Cuesta, Rocío ^a   De Los Rios, Cristóbal ^b   Cano Abad, María F ^a  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Benzothiazepines; Calcium homeostasis modulator 1 (CALHM1); CGP37157; ITH12575; Neurodegenerative diseases

Indexed keywords

7 CHLORO 5 (2 CHLOROPHENYL) 3,5 DIHYDRO 4,1 BENZOTHIAZEPIN 2 (1H) ONE; 7 CHLORO 5 (2 ISOPROPYLPHENYL) 3,5 DIHYDRO 4,1 BENZOTHIAZEPIN 2 (1H) ONE; BENZOTHIAZEPINE DERIVATIVE; CALCIUM CHANNEL; CALCIUM HOMEOSTASIS MODULATOR 1; CALCIUM ION; UNCLASSIFIED DRUG; 7 CHLORO 5 (2 CHLOROPHENYL) 1,5 DIHYDRO 4,1 BENZOTHIAZEPIN 2(3H) ONE; 7-CHLORO-5-(2-ISOPROPYLPHENYL)-3,5-DIHYDRO-4,1-BENZOTHIAZEPIN-2-(1H)-ONE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALHM1 PROTEIN, HUMAN; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; CATION; CLONAZEPAM; COBALT; DIMEBON; INDOLE DERIVATIVE; MEMBRANE PROTEIN; PROTON IONOPHORE; THIAZEPINE DERIVATIVE;

ARTICLE; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SYNTHESIS; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; LIGAND BINDING; NEUROPHARMACOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; X RAY DIFFRACTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MITOCHONDRION; SYNTHESIS;

CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CATIONS; CLONAZEPAM; COBALT; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; INDOLES; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; POLYMORPHISM, GENETIC; PROTON IONOPHORES; THIAZEPINES; TRANSFECTION;

EID: 84930935360     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.02.016     Document Type: Article

References (28)

1. S.O. Bachurin, E.P. Shevtsova, E.G. Kireeva, G.F. Oxenkrug, and S.O. Sablin Mitochondria as a target for neurotoxins and neuroprotective agents Ann. N. Y. Acad. Sci. 993 2003 334 344 Discussion 345-339
2. O. Calero, M.J. Bullido, J. Clarimon, R. Hortiguela, A. Frank-Garcia, P. Martinez-Martin, A. Lleo, M.J. Rey, I. Sastre, A. Rabano, J. de Pedro-Cuesta, I. Ferrer, and M. Calero Genetic variability of the gene cluster CALHM 1-3 in sporadic Creutzfeldt-Jakob disease Prion 6 2012 407 412
3. N. Cano-Cuenca, J.E. Solis-Garcia del Pozo, and J. Jordan Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis J. Alzheimers Dis. 38 2014 155 164
4. M. Chiesi, R. Schwaller, and K. Eichenberger Structural dependency of the inhibitory action of benzodiazepines and related compounds on the mitochondrial Na+-Ca2+ exchanger Biochem. Pharmacol. 37 1988 4399 4403
5. N. Diaz-Prieto, I. Herrera-Peco, A.M. de Diego, A. Ruiz-Nuno, S. Gallego-Sandin, M.G. Lopez, A.G. Garcia, and M.F. Cano-Abad Bcl2 mitigates Ca2+ entry and mitochondrial Ca2+ overload through downregulation of L-type Ca2+ channels in PC12 cells Cell Calcium 44 2008 339 352
6. U. Dreses-Werringloer, J.C. Lambert, V. Vingtdeux, H. Zhao, H. Vais, A. Siebert, A. Jain, J. Koppel, A. Rovelet-Lecrux, D. Hannequin, F. Pasquier, D. Galimberti, E. Scarpini, D. Mann, C. Lendon, D. Campion, P. Amouyel, P. Davies, J.K. Foskett, F. Campagne, and P. Marambaud A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk Cell 133 2008 1149 1161
7. U. Dreses-Werringloer, V. Vingtdeux, H. Zhao, P. Chandakkar, P. Davies, and P. Marambaud CALHM1 controls Ca2+-dependent MEK/ERK/RSK/MSK signaling in neurons J. Cell Sci. 126 2013 1199 1206
8. D.F. Ewing Carbon-13-hydrogen coupling constants. III. Conformation dependence of 1J(13CH) fo r the formyl proton in aromatic aldehydes Org. Magn. Reson. 6 1974 298 300
9. S. Gallego-Sandin, M.T. Alonso, and J. Garcia-Sancho Calcium homoeostasis modulator 1 (CALHM1) reduces the calcium content of the endoplasmic reticulum (ER) and triggers ER stress Biochem. J. 437 2011 469 475
10. V. Giedraitis, A. Glaser, T. Sarajarvi, R. Brundin, M.D. Gunnarsson, B.M. Schjeide, R.E. Tanzi, S. Helisalmi, T. Pirttila, L. Kilander, L. Lannfelt, H. Soininen, L. Bertram, M. Ingelsson, and M. Hiltunen CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid Neurosci. Lett. 469 2010 265 267
11. L. Gonzalez-Lafuente, J. Egea, R. Leon, F.J. Martinez-Sanz, L. Monjas, C. Perez, C. Merino, A.M. Garcia-De Diego, M.I. Rodriguez-Franco, A.G. Garcia, M. Villarroya, M.G. Lopez, and C. de Los Rios Benzothiazepine CGP37157 and its Isosteric 2′-methyl analogue provide neuroprotection and block cell calcium entry ACS Chem. Neurosci. 3 2012 519 529
12. K. Inoue, N. Tanaka, F. Yamashita, Y. Sawano, T. Asada, and Y. Goto The P86L common allele of CALHM1 does not influence risk for Alzheimer disease in Japanese cohorts Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B 2010 532 535
13. J. Koppel, F. Campagne, V. Vingtdeux, U. Dreses-Werringloer, M. Ewers, D. Rujescu, H. Hampel, M.L. Gordon, E. Christen, J. Chapuis, B.S. Greenwald, P. Davies, and P. Marambaud CALHM1 P86L polymorphism modulates CSF Abeta levels in cognitively healthy individuals at risk for Alzheimer's disease Mol. Med. 17 2011 974 979
14. J.C. Lambert, K. Sleegers, A. Gonzalez-Perez, M. Ingelsson, G.W. Beecham, M. Hiltunen, O. Combarros, M.J. Bullido, N. Brouwers, K. Bettens, C. Berr, F. Pasquier, F. Richard, S.T. Dekosky, D. Hannequin, J.L. Haines, G. Tognoni, N. Fievet, J.F. Dartigues, C. Tzourio, S. Engelborghs, B. Arosio, E. Coto, P. De Deyn, M. Del Zompo, I. Mateo, M. Boada, C. Antunez, J. Lopez-Arrieta, J. Epelbaum, B.M. Schjeide, A. Frank-Garcia, V. Giedraitis, S. Helisalmi, E. Porcellini, A. Pilotto, P. Forti, R. Ferri, M. Delepine, D. Zelenika, M. Lathrop, E. Scarpini, G. Siciliano, V. Solfrizzi, S. Sorbi, G. Spalletta, G. Ravaglia, F. Valdivieso, S. Vepsalainen, V. Alvarez, P. Bosco, M. Mancuso, F. Panza, B. Nacmias, P. Bossu, O. Hanon, P. Piccardi, G. Annoni, D. Mann, P. Marambaud, D. Seripa, D. Galimberti, R.E. Tanzi, L. Bertram, C. Lendon, L. Lannfelt, F. Licastro, D. Campion, M.A. Pericak-Vance, H. Soininen, C. Van Broeckhoven, A. Alperovitch, A. Ruiz, M.I. Kamboh, and P. Amouyel The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study J. Alzheimers Dis. 22 2010 247 255
15. N.N. Lermontova, A.E. Redkozubov, E.F. Shevtsova, T.P. Serkova, E.G. Kireeva, and S.O. Bachurin Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels Bull. Exp. Biol. Med. 132 2001 1079 1083
16. R.J. Lv, J.S. He, Y.H. Fu, X.Q. Shao, L.W. Wu, Q. Lu, L.R. Jin, and H. Liu A polymorphism in CALHM1 is associated with temporal lobe epilepsy Epilepsy Behav. 20 2011 681 685
17. Z. Ma, A.P. Siebert, K.H. Cheung, R.J. Lee, B. Johnson, A.S. Cohen, V. Vingtdeux, P. Marambaud, and J.K. Foskett Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca2+ regulation of neuronal excitability Proc. Natl. Acad. Sci. U. S. A. 109 2012 E1963 E1971
18. P. Mitchell, and J. Moyle Acid-base titration across the membrane system of rat-liver mitochondria. Catalysis by uncouplers Biochem. J. 104 1967 588 600
19. A.J. Moreno-Ortega, A. Ruiz-Nuno, A.G. Garcia, and M.F. Cano-Abad Mitochondria sense with different kinetics the calcium entering into HeLa cells through calcium channels CALHM1 and mutated P86L-CALHM1 Biochem. Biophys. Res. Commun. 391 2010 722 726
20. S.M. Nicolau, A.M. de Diego, L. Cortes, J. Egea, J.C. Gonzalez, M. Mosquera, M.G. Lopez, J.M. Hernandez-Guijo, and A.G. Garcia Mitochondrial Na+/Ca2+-exchanger blocker CGP37157 protects against chromaffin cell death elicited by veratridine J. Pharmacol. Exp. Ther. 330 2009 844 854
21. S.M. Nicolau, J. Egea, M.G. Lopez, and A.G. Garcia Mitochondrial Na+/Ca2+ exchanger, a new target for neuroprotection in rat hippocampal slices Biochem. Biophys. Res. Commun. 400 2010 140 144
22. Y. Pei, M.J. Lilly, D.J. Owen, L.J. D'Souza, X.Q. Tang, J. Yu, R. Nazarbaghi, A. Hunter, C.M. Anderson, S. Glasco, N.J. Ede, I.W. James, U. Maitra, S. Chandrasekaran, W.H. Moos, and S.S. Ghosh Efficient syntheses of benzothiazepines as antagonists for the mitochondrial sodium-calcium exchanger: potential therapeutics for type II diabetes J. Org. Chem. 68 2003 92 103
23. M.I. Ragone, N.S. Torres, and A.E. Consolini Energetic study of cardioplegic hearts under ischaemia/reperfusion and [Ca(2+)] changes in cardiomyocytes of guinea-pig: mitochondrial role Acta Physiol. (Oxf.) 207 2013 369 384
24. P.C. Roosen, V.A. Kallepalli, B. Chattopadhyay, D.A. Singleton, R.E. Maleczka Jr., and M.R. Smith 3rd Outer-sphere direction in iridium C-H borylation J. Am. Chem. Soc. 134 2012 11350 11353
25. J.E. Tanis, Z. Ma, P. Krajacic, L. He, J.K. Foskett, and T. Lamitina CLHM-1 is a functionally conserved and conditionally toxic Ca2+-permeable ion channel in Caenorhabditis elegans J. Neurosci. 33 2013 12275 12286
26. Q.Q. Tao, Y.M. Sun, Z.J. Liu, P. Yang, H.L. Li, S.J. Lu, and Z.Y. Wu Lack of association between CALHM1 p.P86L variation and Alzheimer's disease in the Han Chinese population Neurobiol. Aging 35 1956 2014 e1913 1954
27. A. Taruno, V. Vingtdeux, M. Ohmoto, Z. Ma, G. Dvoryanchikov, A. Li, L. Adrien, H. Zhao, S. Leung, M. Abernethy, J. Koppel, P. Davies, M.M. Civan, N. Chaudhari, I. Matsumoto, G. Hellekant, M.G. Tordoff, P. Marambaud, and J.K. Foskett CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes Nature 495 2013 223 226
28. M.G. Tordoff, H.T. Ellis, T.R. Aleman, A. Downing, P. Marambaud, J.K. Foskett, R.M. Dana, and S.A. McCaughey Salty taste deficits in CALHM1 knockout mice Chem. Senses 39 2014 515 528